Overview

Clonal Deletion on Living-Relative Donor Kidney Transplantation

Status:
Unknown status
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to determine if clonal deletion before kidney transplantation can effectively reduce the need for post transplant immunosuppression. The investigators will adapt a DAWN (Drugs (immunosuppressants) Added When Needed) treatment protocol to assess the effect of clonal deletion and closely monitor acute rejection, renal function, and graft survival. 15 patients eligible for the study as described below will be enrolled.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fuzhou General Hospital
Collaborator:
Terasaki Foundation
Treatments:
Bortezomib